Priorities & Actions
Parkinson's Plan 2006
Parkinson's Matrix
Research Agenda

Research Resources

Animal Models

Antibody Resources
Clinical Research
Gene Therapy
Genetic Resources
Brain Banks Across the
   United States

Funding Research
Funding Announcements
Clinical Trials
Related Literature

Research Centers
NIH Intramural Research
Udall Centers of
   Excellence

Patient/Caregiver Information
Parkinson's Disease
PD Clinical Trials

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

Join our electronic mailing list

RATS

AAV Synuclein Model

Gene	Vector	Phenotype	Reference
α-syn: WT, A53T	rAAV α-syn with chicken β-actin promoter. Injected stereotactically into right substantia nigra.	Progressive loss of dopamine, dopamine neurons, TH. α-syn inclusion bodies. Motor impairment.	Kirik, et al. J Neurosci 2002; 22(7):2780-91.

 

Chemical lesion models*

Chemical	Administration	Phenotype	Reference
6-OHDA	Injected stereotactically into nigra or striatum.	Acute cell nigrostriatal dopamine depletion. Rotational behavior in response to amphetamine or apomorphine.	Onn et al. Brain Res 1986;376(1):8-19. Perese, et al. Brain Res. 1989; 494:285-293. Przedborski, et al. Neuroscience 1995; 67:631-647.
Rotenone	Systemic	Chronic nigrostriatal cell loss, dopamine depletion, -syn inclusion bodies. Akinesia, rigidity, tremor, flexed posture, piloerection.	Betarbet, et al. Nat Neurosci 2000; (12):1301-6.

*Note: rats are resistant to MPTP.

Last updated February 10, 2006